Whitepaper

Remdesivir: A Classic Analysis of Desperate Measures During Desperate Times

Market Research

An analysis of the surge in demand for Remdesivir, as a COVID-19 drug. Was the surge driven by market preferences, perception, and push by few people? The rise of Remdesivir in 2020 is a classic example of what social media sentiments, medical data (or sales without medical data), and public perception are capable of doing in desperate times.

 

Key Points

  • In 2020, medical devices and surgical accessories suppliers registered losses as elective and non-elective surgeries were postponed extensively all over the US.
  • According to HHS, the US had secured >500,000 treatment courses of Remdesivir in September 2020. This has exhausted the stock of Gilead for 3 months.
  • Recently, HEOR has put the cost of COVID intensive-care treatment at around USD 20,000. If the drug shortens an ICU stay by 30%, then there might be a justification for a USD 5,000 price for the drug.

To know more...



Authors

Dr. Siddhartha Dutta

Dr. Sidhartha Dutta is a business technologist...

Related Topics

The Evolving Landscape of Lead Generation

Whitepapers

The Evolving Landscape of Lead Generation

In today’s competitive business landscape, generating high-quality leads is a cornerstone of sustainable growth. Leads are potential customers who...

ATxSG Broadcast Asia 2024

Whitepapers

ATxSG BroadcastAsia 2024: Key Trends

ATxSG is one of the leading technology conferences in Asia-Pacific with two primary focus avenues, i.e., BroadcastAsia and CommunicAsia, with close to...

NAB 2024 Key Trends

Whitepapers

NAB 2024 Key Trends

SG Analytics (SGA)’s media and broadcast research & consulting team surveyed 13 vendors attending the 2024 NAB Show in Las Vegas in April 2024....

VIEW MORE

We bring comprehensive data driven insights to everyone, everywhere